Open AccessMicro RNA s: A novel potential biomarker for diagnosis and therapy in patients with non‐small cell lung cancer
Author(s) -
Zhou Qun,
Huang ShaoXin,
Zhang Feng,
Li ShuJun,
Liu Cong,
Xi YongYong,
Wang Liang,
Wang Xin,
He QiQiang,
Sun ChengCao,
Li DeJia
Publication year - 2017
Publication title -
cell proliferation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.647
H-Index - 74
eISSN - 1365-2184
pISSN - 0960-7722
DOI - 10.1111/cpr.12394
Subject(s) - rna , lung cancer , microrna , non coding rna , biomarker , medicine , long non coding rna , cancer , cancer research , biology , gene , oncology , genetics
Background Lung cancer is still one of the most serious causes of cancer‐related deaths all over the world. Micro RNA s (mi RNA s) are defined as small non‐coding RNA s which could play a pivotal role in post‐transcriptional regulation of gene expression. Increasing evidence demonstrated dysregulation of mi RNA expression associates with the development and progression of NSCLC . Aims To emphasize a variety of tissue‐specific mi RNA s, circulating mi RNA s and mi RNA ‐derived exosomes could be used as potential diagnostic and therapeutic biomarkers in NSCLC patients. Materials & Methods In the current review, we paid attention to the significant discoveries of preclinical and clinical studies, which performed on tissue‐specific mi RNA , circulating mi RNA and exosomal mi RNA . The related studies were obtained through a systematic search of Pubmed, Web of Science, Embase. Results A variety of tissue‐specific mi RNA s and circulating mi RNA s with high sensitivity and specificity which could be used as potential diagnostic and therapeutic biomarkers in NSCLC patients. In addition, we emphasize that the mi RNA ‐derived exosomes become novel diagnostic biomarkers potentially in these patients with NSCLC . Conclusion Mi RNA s have emerged as non‐coding RNA s, which have potential to be candidates for the diagnosis and therapy of NSCLC .